Scheduling
Scheduling is a national classification system that controls how medicines and chemicals are made available to the consumers in order to protect public health.
Medicines and chemicals are classified into Schedules according to the level of regulatory control over the availability of the medicine or chemical required to protect public health and safety. The Schedules are published in the Poisons Standard and are given legal effect through state and territory legislation.
For details go to Scheduling of medicines & poisons.
Key information
Scheduling
- Scheduling basics
- Advisory Committee on Chemicals Scheduling
- Advisory Committee on Medicines Scheduling
- Public notices about scheduling
- Update on Psilocybin and MDMA scheduling
- Implementation of decisions and actions following the review of chemical scheduling in relation to cosmetic and fragrance ingredients
- Scheduling legislation
- Scheduling news
Poisons Standard
- Introduction to the Poisons Standard
- The Poisons Standard (the SUSMP)
- AHMAC - Scheduling policy framework for medicines and chemicals
- Scheduling handbook: Guidance for amending the Poisons Standard
State and territory information
- State/Territory scheduling information
- Contacts for State/Territory medicines & poisons regulation units
- Australian State & Territory regulatory controls on Schedule 7 poisons
- Australian State & Territory variations from Part 4 of the Poisons Standard
Amending the Poisons Standard and consultation coversheets
- Scheduling handbook: Guidance for amending the Poisons Standard
- Application to amend the Poisons Standard
- Scheduling consultation coversheets
Reports
- Independent Expert Panel on MDMA and psilocybin
- Independent expert report on the risks of intentional self-poisoning with paracetamol
- An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders
- Regulatory options for appropriate access and safety controls for alkyl nitrites - Public meeting questions and answers
Latest articles
- Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatristsFrom 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.
- TGA makes interim decision to reduce maximum paracetamol pack sizesThe TGA has today published an interim decision to reduce the maximum pack sizes for various paracetamol products.
- Independent review of paracetamol overdoseThe TGA has published an independent expert report examining the incidence of serious injury and death from intentional paracetamol overdose.
Latest publications
- Notice of final decision to amend (or not amend) the current Poisons Standard - June 2022 ACMS #38 - Psilocybine and MDMAPublic notice of final decisions to amend (or not amend) the Poisons Standard - ACMS, June 2022
- Public submissions on interim decisions for scheduling matters referred to the ACMS #38, ACCS #34 and Joint ACMS-ACCS #31 held in June 2022 (including MDMA and psilocybine)Public submissions on interim decisions for scheduling matters referred to ACMS, ACCS and Joint meetings held in June 2022
- Public notice of interim decisions on proposed amendments to the Poisons Standard - ACMS#40, ACCS#35, Joint ACMS-ACCS#32 - November 2022Interim decisions and invitation for further comment. Closing date: 3 March 2023